Vivos Historical Income Statement

VVOS Stock

USD 3.41 0.01 0.29%

Historical analysis of Vivos Therapeutics income statement accounts such as Tax Provision of 0.0, Net Interest Income of 0.0, Interest Income of 141.3 K or Depreciation And Amortization of 549.9 K can show how well Vivos Therapeutics performed in making a profits. Evaluating Vivos Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Vivos Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Vivos Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Vivos Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vivos Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Vivos Stock please use our How to Invest in Vivos Therapeutics guide.

About Vivos Income Statement Analysis

Vivos Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Vivos Therapeutics shareholders. The income statement also shows Vivos investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Vivos Therapeutics Income Statement Chart

At this time, Vivos Therapeutics' Interest Income is comparatively stable compared to the past year. Interest Expense is likely to gain to about 1.4 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 549.9 K in 2024.

Selling And Marketing Expenses Total Revenue Gross Profit

Total Revenue

Total revenue comprises all receipts Vivos Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Vivos Therapeutics minus its cost of goods sold. It is profit before Vivos Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Most accounts from Vivos Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Vivos Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vivos Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Vivos Stock please use our How to Invest in Vivos Therapeutics guide.At this time, Vivos Therapeutics' Interest Income is comparatively stable compared to the past year. Interest Expense is likely to gain to about 1.4 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 549.9 K in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	14K	1.2M	1.4M	1.4M
Depreciation And Amortization	733K	669K	621K	549.9K

Interest Expense Depreciation And Amortization

Vivos Therapeutics income statement Correlations

	Net Interest Income	Depreciation And Amortization	Interest Expense	Selling General Administrative	Selling And Marketing Expenses	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Reconciled Depreciation	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Research Development
Net Interest Income		0.32	0.47	0.87	0.89	0.87	0.86	0.87	-0.81	-0.87	-0.86	-0.86	0.79	0.88	0.39	-0.85	0.5	-0.82	-0.48	-0.4
Depreciation And Amortization	0.32		-0.25	0.4	0.45	0.53	0.62	0.4	-0.2	-0.35	-0.28	-0.27	0.29	0.42	0.99	-0.41	-0.31	-0.35	-0.24	0.33
Interest Expense	0.47	-0.25		0.69	0.5	0.6	0.46	0.69	-0.75	-0.65	-0.72	-0.73	0.81	0.65	-0.2	-0.56	0.94	-0.57	-0.41	-0.83
Selling General Administrative	0.87	0.4	0.69		0.95	0.96	0.91	1.0	-0.96	-0.98	-0.98	-0.98	0.96	1.0	0.45	-0.96	0.6	-0.94	-0.48	-0.45
Selling And Marketing Expenses	0.89	0.45	0.5	0.95		0.91	0.89	0.95	-0.93	-0.97	-0.95	-0.95	0.83	0.97	0.48	-0.98	0.4	-0.97	-0.36	-0.21
Total Revenue	0.87	0.53	0.6	0.96	0.91		0.98	0.96	-0.85	-0.91	-0.91	-0.9	0.92	0.96	0.58	-0.88	0.56	-0.84	-0.6	-0.44
Gross Profit	0.86	0.62	0.46	0.91	0.89	0.98		0.9	-0.76	-0.85	-0.83	-0.83	0.82	0.91	0.65	-0.83	0.43	-0.78	-0.61	-0.32
Other Operating Expenses	0.87	0.4	0.69	1.0	0.95	0.96	0.9		-0.96	-0.98	-0.98	-0.98	0.96	1.0	0.45	-0.96	0.6	-0.94	-0.47	-0.44
Operating Income	-0.81	-0.2	-0.75	-0.96	-0.93	-0.85	-0.76	-0.96		0.98	0.99	0.99	-0.92	-0.96	-0.25	0.95	-0.63	0.97	0.32	0.44
Net Income From Continuing Ops	-0.87	-0.35	-0.65	-0.98	-0.97	-0.91	-0.85	-0.98	0.98		0.99	0.99	-0.91	-0.99	-0.39	0.99	-0.52	0.98	0.43	0.33
Ebit	-0.86	-0.28	-0.72	-0.98	-0.95	-0.91	-0.83	-0.98	0.99	0.99		1.0	-0.94	-0.98	-0.32	0.97	-0.61	0.96	0.44	0.42
Ebitda	-0.86	-0.27	-0.73	-0.98	-0.95	-0.9	-0.83	-0.98	0.99	0.99	1.0		-0.94	-0.98	-0.32	0.97	-0.61	0.96	0.44	0.43
Cost Of Revenue	0.79	0.29	0.81	0.96	0.83	0.92	0.82	0.96	-0.92	-0.91	-0.94	-0.94		0.94	0.36	-0.86	0.74	-0.85	-0.5	-0.62
Total Operating Expenses	0.88	0.42	0.65	1.0	0.97	0.96	0.91	1.0	-0.96	-0.99	-0.98	-0.98	0.94		0.47	-0.97	0.56	-0.95	-0.46	-0.39
Reconciled Depreciation	0.39	0.99	-0.2	0.45	0.48	0.58	0.65	0.45	-0.25	-0.39	-0.32	-0.32	0.36	0.47		-0.45	-0.26	-0.38	-0.29	0.27
Income Before Tax	-0.85	-0.41	-0.56	-0.96	-0.98	-0.88	-0.83	-0.96	0.95	0.99	0.97	0.97	-0.86	-0.97	-0.45		-0.41	0.98	0.4	0.21
Total Other Income Expense Net	0.5	-0.31	0.94	0.6	0.4	0.56	0.43	0.6	-0.63	-0.52	-0.61	-0.61	0.74	0.56	-0.26	-0.41		-0.43	-0.38	-0.96
Net Income	-0.82	-0.35	-0.57	-0.94	-0.97	-0.84	-0.78	-0.94	0.97	0.98	0.96	0.96	-0.85	-0.95	-0.38	0.98	-0.43		0.24	0.24
Income Tax Expense	-0.48	-0.24	-0.41	-0.48	-0.36	-0.6	-0.61	-0.47	0.32	0.43	0.44	0.44	-0.5	-0.46	-0.29	0.4	-0.38	0.24		0.31
Research Development	-0.4	0.33	-0.83	-0.45	-0.21	-0.44	-0.32	-0.44	0.44	0.33	0.42	0.43	-0.62	-0.39	0.27	0.21	-0.96	0.24	0.31

Click cells to compare fundamentals

Vivos Therapeutics Account Relationship Matchups

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Vivos Stock Analysis

When running Vivos Therapeutics' price analysis, check to measure Vivos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivos Therapeutics is operating at the current time. Most of Vivos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vivos Therapeutics' price. Additionally, you may evaluate how the addition of Vivos Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Vivos Historical Income Statement

About Vivos Income Statement Analysis

Vivos Therapeutics Income Statement Chart

Total Revenue

Gross Profit

Vivos Therapeutics income statement Correlations

Vivos Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Vivos Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Tax Provision	Net Interest Income
Interest Income	Depreciation And Amortization
Interest Expense	Selling General Administrative
Selling And Marketing Expenses	Total Revenue
Gross Profit	Other Operating Expenses
Operating Income	Net Income From Continuing Ops
Ebit	Ebitda
Cost Of Revenue	Total Operating Expenses
Reconciled Depreciation	Income Before Tax
Total Other Income Expense Net	Net Income Applicable To Common Shares
Net Income	Income Tax Expense
Research Development

Other Operating Expenses	+ 1.0	Selling General Administrative
Total Operating Expenses	+ 1.0	Selling General Administrative
Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebitda	+ 1.0	Ebit
Reconciled Depreciation	+ 0.99	Depreciation And Amortization
Ebit	+ 0.99	Operating Income

Total Operating Expenses	- 0.99	Net Income From Continuing Ops
Total Operating Expenses	- 0.98	Ebitda
Total Operating Expenses	- 0.98	Ebit
Ebitda	- 0.98	Other Operating Expenses
Ebit	- 0.98	Other Operating Expenses
Net Income From Continuing Ops	- 0.98	Other Operating Expenses